BioPharma, Pharma Longboard Pharma Trial Data Show How It Could Stand Out in the Epilepsy Field By Frank Vinluan
BioPharma, Pharma FDA approves Marinus Pharma drug for rare, genetic form of epilepsy By Frank Vinluan
BioPharma, Pharma Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med By Frank Vinluan
Daily, Pharma, BioPharma UCB is expanding its reach in epilepsy with $1.9B Zogenix acquisition By Frank Vinluan
BioPharma, Pharma Ovid Therapeutics adds to epilepsy drug pipeline with new AstraZeneca alliance By Frank Vinluan
MedCity Influencers, Artificial Intelligence The role of AI in advancing neuromodulation treatment for epilepsy By Bipin Patel
BioPharma, Devices & Diagnostics, Startups Neuroelectrics gets $17M for new take on electrical therapy for epilepsy, depression By Frank Vinluan
BioPharma Ovid drug reduces seizure frequency in two rare forms of epilepsy, according to early Phase II data By Alaric DeArment
BioPharma, Policy Marinus scores in Phase III genetic epilepsy drug study, wins BARDA contract for IV formulation By Alaric DeArment
Health IT, BioPharma LunaPBC, Genetic Alliance create drug discovery platform for rare epilepsy By Elise Reuter
BioPharma, Policy GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval By Alaric DeArment
BioPharma GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory By Alaric DeArment
Pharma Convenient timing, Shkreli: Turing’s epilepsy drug gets fast-tracked by FDA By Meghana Keshavan
